A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

DSpace Repository

Show simple item record

dc.contributor.author Stenzl, Arnulf
dc.date.accessioned 2017-07-13T07:11:47Z
dc.date.available 2017-07-13T07:11:47Z
dc.date.issued 2016
dc.identifier.issn 1423-0399
dc.identifier.uri http://hdl.handle.net/10900/76945
dc.language.iso en en
dc.publisher Karger de_DE
dc.relation.uri http://dx.doi.org/10.1159/000381589
dc.rights info:eu-repo/semantics/closedAccess
dc.subject.ddc 610 de_DE
dc.title A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium de_DE
dc.type Artikel de_DE
utue.quellen.id 20160915142648_02310
utue.publikation.seiten 5-13 de_DE
utue.personen.roh Miller, Kurt
utue.personen.roh Morant, Rudolf
utue.personen.roh Stenzl, Arnulf
utue.personen.roh Zuna, Ivan
utue.personen.roh Wirth, Manfred
dcterms.isPartOf.ZSTitelID Urologia Internationalis de_DE
dcterms.isPartOf.ZS-Issue 1 de_DE
dcterms.isPartOf.ZS-Volume 96 de_DE
utue.fakultaet 04 Medizinische Fakultät


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record